Reactive oxygen and nitrogen species induce protein and DNA modifications driving arthrofibrosis following total knee arthroplasty

Fibrogenesis and Tissue Repair

Volumn 2, Issue 1, 2009, Pages

  Freeman, Theresa A ^a   Parvizi, Javad ^b   Della Valle, Craig J ^c   Steinbeck, Marla J ^d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650178328     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-2-5     Document Type: Article

References (66)

1. Bong MR, Di Cesare PE. Stiffness after total knee arthroplasty. Journal of the American Academy of Orthopaedic Surgeons 2004, 12:164-171.
2. Laskin RS, Beksac B. Stiffness after total knee arthroplasty. Journal of Arthroplasty 2004, 19:41-46.
3. Yercan HS, Sugun TS, Bussiere C, Ait Si Selmi T, Davies A, Neyret P. Stiffness after total knee arthroplasty: prevalence, management and outcomes. Knee 2006, 13:111-117.
4. Kim J, Nelson CL, Lotke PA. Stiffness after total knee arthroplasty. Prevalence of the complication and outcomes of revision. Journal of Bone & Joint Surgery American 2004, 86:1479-1484.
5. Anouchi YS, McShane M, Kelly F, Elting J, Stiehl J. Range of motion in total knee replacement. Clinical Orthopaedics & Related Research 1996, 331:87-92.
6. Diduch DR, Scuderi GR, Scott WN, Insall JN, Kelly MA. The efficacy of arthroscopy following total knee replacement. Arthroscopy 1997, 13:166-171.
7. Markel DC, Luessenhop CP, Windsor RE, Sculco TA. Arthroscopic treatment of peripatellar fibrosis after total knee arthroplasty. Journal of Arthroplasty 1996, 11:293-297.
8. Mont MA, Serna FK, Krackow KA, Hungerford DS. Exploration of radiographically normal total knee replacements for unexplained pain. Clinical Orthopaedics & Related Research 1996, 331:216-220.
9. Nicholls DW, Dorr LD. Revision surgery for stiff total knee arthroplasty. Journal of Arthroplasty 1990, 5(Suppl):S73-7.
10. Ries MD, Badalamente M. Arthrofibrosis after total knee arthroplasty. Clinical Orthopaedics & Related Research 2000, 380:177-183.
11. Parvizi J, Tarity TD, Steinbeck MJ, Politi RG, Joshi A, Purtill JJ, Sharkey PF. Management of stiffness following total knee arthroplasty. Journal of Bone and Joint Surgery 2006, 88:175-181.
12. Furia JP, Pellegrini VD. Heterotopic ossification following primary total knee arthroplasty [see comment]. Journal of Arthroplasty 1995, 10:413-419.
13. Freeman TA, Parvizi J, Della Valle C, Steinbeck MJ. Mast cells and hypoxia drive tissue metaplasia and heterotopic ossification in idiopathic arthrofibrosis. Fibrogenesis and Tissue Repair 2009, Submitted.
14. Wynn TA. Fibrotic disease and the th1/th2 paradigm. Nature Reviews Immunology 2004, 4:583-594. 2702150, 15286725.
15. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. Journal of Immunology 2001, 166:7556-7562.
16. Stramer BM, Mori R, Martin P. The inflammation-fibrosis link? A Jekyll and Hyde role for blood cells during wound repair. Journal of Investigative Dermatology 2007, 127:1009-1017.
17. Martin P, Leibovich SJ. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends in Cell Biol 2005, 15:599-607.
18. Baran CP, Zeigler MM, Tridandapani S, Marsh CB. The role of ROS and RNS in regulating life and death of blood monocytes. Current Pharmaceutical Design 2004, 10:855-866.
19. Cochrane AL, Ricardo SD. Oxidant stress and regulation of chemokines in the development of renal interstitial fibrosis. Contributions to Nephrology 2003, 139:102-119.
20. Diamond JR, Ricardo SD, Klahr S. Mechanisms of interstitial fibrosis in obstructive nephropathy. Seminars in Nephrology 1998, 18:594-602.
21. Ferrini MG, Vernet D, Magee TR, Shahed A, Qian A, Rajfer J, Gonzalez-Cadavid NF. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 2002, 6:283-294.
22. Marsh CB, Kelley TW, Graham MM, Dong C, Goldschmidt-Clermont PJ. Monocytes may regulate tissue fibrosis. Chest 2001, 120:15S-16S.
23. Poli G. Pathogenesis of liver fibrosis: role of oxidative stress. Molecular Aspects of Medicine 2000, 21:49-98.
24. Poli G, Parola M. Oxidative damage and fibrogenesis. Free Radical Biology & Medicine 1997, 22:287-305.
25. Ricardo SD, Diamond JR. The role of macrophages and reactive oxygen species in experimental hydronephrosis. Seminars in Nephrology 1998, 18:612-621.
26. Swindle EJ, Hunt JA, Coleman JW. A comparison of reactive oxygen species generation by rat peritoneal macrophages and mast cells using the highly sensitive real-time chemiluminescent probe pholasin: inhibition of antigen-induced mast cell degranulation by macrophage-derived hydrogen peroxide. Journal of Immunology 2002, 169:5866-5873.
27. Puxeddu I, Piliponsky AM, Bachelet I, Levi-Schaffer F. Mast cells in allergy and beyond. International Journal of Biochemistry and Cell Biology 2003, 35:1601-1607.
28. Murrell GA. The role of the fibroblast in Dupuytren's contracture. Hand Clinics 1991, 7:669-680.
29. Murrell GA. Scientific comment. Basic science of Dupuytren's disease. Annales de Chirurgie de la Main et du Membre Superieur 1992, 11:355-361.
30. Murrell GA. An insight into Dupuytren's contracture. Annals of the Royal College of Surgeons of England 1992, 74:156-160. 2497584, 1616255.
31. Yi IS, Johnson G, Moneim MS. Etiology of Dupuytren's disease. Hand Clinics 1999, 15:43-51.
32. Cracowski J-L. Isoprostanes as a tool to investigate oxidative stress in scleroderma spectrum disorders--advantages and limitations. Rheumatology 2006, 45:922-923.
33. Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G, Gabrielli A. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway [see comment]. Arthritis & Rheumatism 2001, 44:2653-2664.
34. Kruidenier L, Kuiper I, Van Duijn W, Mieremet-Ooms MA, van Hogezand RA, Lamers CB, Verspaget HW. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. Journal of Pathology 2003, 201:17-27.
35. Risques RA, Rabinovitch PS, Brentnall TA. Cancer surveillance in inflammmatory bowel disease: new molecular approaches. Current Opinion in Gastroenterology 2006, 22:382-390.
36. Harrison JE, Schultz J. Studies on the chlorinating activity of myeloperoxidase. Journal of Biological Chemistry 1976, 251:1371-1374. 176150.
37. Halliwell B. Oxidative stress and cancer: have we moved forward?. Biochem J 2007, 401:1-11. 17150040.
38. Heijnem HF, van Donselaar E, Slot JW, Fries DM, Blachard-Fillion B, Hodara R, Lightfoot R, Polydoro M, Spielberg DL, et al. Subcellular localization of tyrosine-nitrated proteins is dictated by reactive oxygen species generating enzymes and by proximity to nitric oxide synthase. Free Radical Biology & Medicine 2006, 40:1903-1913. 16716892.
39. van Dalen CJ, Winterbourn CC, Senthilmohan R, Kettle AJ. Nitrite as a substrate and inhibitor of myeloperoxidase. Implications for nitration and hypochlorous acid production at sites of inflammation. J Biol Chem 2000, 275:11638-11644.
40. Takeshita J, Byun J, Nhan TQ, Pritchard DK, Pennathur S, Schwartz SM, Chait A, Heinecke JW. Myeloperoxidase generates 5-chlorouracil in human atherosclerotic tissue: a potential pathway for somatic mutagenesis by macrophages. J Biol Chem 2006, 281:3096-3104.
41. Henderson JP, Byun J, Takeshita J, Heinecke JW. Phagocytes produce 5-chlorouracil and 5-bromouracil, two mutagenic products of myeloperoxidase, in human inflammatory tissue. J Biol Chem 2003, 278:23522-23528.
42. Fitzgerald AM, Kirkpatrick JJ, Naylor IL. Dupuytren's disease. The way forward?. Journal of Hand Surgery British 1999, 24:395-399.
43. Murrell GA, Hueston JT. Aetiology of Dupuytren's contracture. Australian & New Zealand Journal of Surgery 1990, 60:247-252.
44. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. Journal of Clinical Investigation 2007, 117:524-529. 1804380, 17332879.
45. Murakami S, Muneta T, Furuya K, Saito I, Miyasaka N, Yamamoto H. Immunohistologic analysis of synovium in infrapatellar fat pad after anterior cruciate ligament injury. The American Journal of Sports Medicine 1995, 23:763-768.
46. Bosch U, Zeichen J, Skutek M, Haeder L, van Griensven M. Arthrofibrosis is the result of a T cell mediated immune response. Knee Surgery, Sports Traumatology, Arthroscopy 2001, 9:282-289.
47. Howard PS, Renfrow D, Schechter NM, Kucich U. Mast cell chymase is a possible mediator of neurogenic bladder fibrosis. Neurourology & Urodynamics 2004, 23:374-382.
48. Kaplan FS, Glaser DL, Hebela N, Shore EM. Heterotopic ossification. Journal of the American Academy of Orthopaedic Surgeons 2004, 12:116-125.
49. Kubiak EN, Moskovich R, Errico TJ, Di Cesare PE. Orthopaedic management of ankylosing spondylitis. Journal of the American Academy of Orthopaedic Surgeons 2005, 13:267-278.
50. Liu K, Tripp S, Layfield LJ. Heterotopic ossification: review of histologic findings and tissue distribution in a 10-year experience. Pathology, Research & Practice 2007, 203:633-640.
51. Rifas L. T-cell cytokine induction of BMP-2 regulates human mesenchymal stromal cell differentiation and mineralization. Journal of Cellular Biochemistry 2006, 98:706-714.
52. Steiner I, Kasparova P, Kohout A, Dominik J. Bone formation in cardiac valves: a histopathological study of 128 cases. Virchows Archiv 2007, 450:653-657.
53. Darley-Usmar V, Wiseman H, Halliwell B. Nitric oxide and oxygen radicals: a question of balance. FEBS Letters 1995, 369:131-135.
54. Brown GC, Borutaite V. Interactions between nitric oxide, oxygen, reactive oxygen species and reactive nitrogen species. Biochem Society Transactions 2006, 34:953-956.
55. Hurst JK, Barrette WC. Leukocytic oxygen activation and microbicidal oxidative toxins. Critical Reviews in Biochemistry & Molecular Biology 1989, 24:271-328.
56. Daumer KM, Khan AU, Steinbeck MJ. Chlorination of pyridinium compounds. Possible role of hypochlorite, N-chloramines, and chlorine in the oxidation of pyridinoline cross-links of articular cartilage collagen type II during acute inflammation. Journal of Biological Chemistry 2000, 275:34681-34692.
57. Steinbeck MJ, Nesti LJ, Sharkey PF, Parvizi J. Myeloperoxidase and chlorinated peptides in osteoarthritis: potential biomarkers of the disease. J Ortho Res 2007, 25:1128-1135.
58. Reynolds WF, Patel K, Pianko S, Blatt LM, Nicholas JJ, McHutchison JG. A genotypic association implicates myeloperoxidase in the progression of hepatic fibrosis in chronic hepatitis c virus infection. Genes and Immunity 2002, 3:345-349.
59. Reynolds WF, Sermet-Gaudelus I, Gausson V, Feuillet M-N, Bonnefont J-P, Descamps-Latscha B, Witko-Sarsat V. Myeloperoxidase promoter polymorphism -463G is associated with more severe clinical expression of cystic fibrosis pulmonary disease. Mediators of Inflammation 2006, 36735:1-8.
60. Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy?. Matrix Biology 2002, 21:473-482.
61. Schafer M, Werner S. Oxidative stress in normal and impaired wound repair. Pharmacological Research 2008, 58:165-171.
62. Hazra TK, Das A, Das S, Choudhury S, Kow YW, Roy R. Oxidative DNA damage repair in mammalian cells: a new perspective. DNA Repair 2007, 6:470-480. 2702509, 17116430.
63. Mustacich D, Powis G. Thioredoxin reductase. Biochem J 2000, 346:1-8. 1220815, 10657232.
64. Yu YP, Yu G, Tseng G, Cieply K, Nelson J, Defrances M, Zarnegar R, Michalopoulos G, Luo J-H. Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res 2007, 67:8043-8050.
65. Scanzello CR, Plaas A, Crow MK. Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound?. Current Opinion in Rheumatology 2008, 20:565-572.
66. Jones KL, Tarochione-Utt KD. DNA methylation in bovine adult and fetal fibroblast cells. Cloning & Stem Cells 2004, 6:259-266.